We are live on ! Find out more
TECH icon

Bio-Techne

72.31 USD
+0.23
0.32%
At close Updated Sep 11, 10:45 AM EDT
1 day
0.32%
5 days
-0.12%
1 month
0.22%
3 months
33.86%
6 months
34.86%
Year to date
21.22%
1 year
35.9%
5 years
-42.45%
10 years
168.11%
 

About: Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Employees: 3,000

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 36.7%
Neutral 60%
Negative 3.3%
Neutral
GlobeNewsWire
1 day ago
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Bio-Techne Corporation (Nasdaq – TECH)
BALA CYNWYD, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Bio-Techne Corporation (Nasdaq – TECH)
Neutral
PRNewsWire
10 days ago
Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals
Fiscal 2026 highlights: Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targets Market-based Scope 1 and 2 emissions reduced 49% year-over-year More than half of the company's electricity consumption now comes from renewable sources First comprehensive Scope 3 emissions inventory completed MINNEAPOLIS, Sept. 1, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced significant progress toward its climate and sustainability objectives, including validation of its greenhouse gas reduction targets by the Science Based Targets initiative (SBTi) and substantial reductions in operational emissions during fiscal year 2026.
Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals
Neutral
GlobeNewsWire
17 days ago
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH)
BALA CYNWYD, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH)
Neutral
Business Wire
20 days ago
TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Bio-Techne Corporation (NASDAQ: TECH) to Merck KGaA for $73.00 per share in cash. Halper Sadeh encourages Bio-Techne shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Bio-Techne and its board of directors violat.
TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders
Positive
Zacks Investment Research
29 days ago
TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises
Bio-Techne's Q4 revenues beat estimates as Diagnostics and Spatial Biology deliver strong organic growth, while its Merck deal remains in focus.
TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises
Neutral
PRNewsWire
29 days ago
Bio-Techne Corrects Dividend Announcement
MINNEAPOLIS, Aug. 13, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is issuing a correction to its dividend announcement released yesterday. The initial version incorrectly stated the shareholder of record date as August 17, 2026.
Bio-Techne Corrects Dividend Announcement
Positive
Zacks Investment Research
1 month ago
Techne (TECH) Q4 Earnings Meet Estimates
Techne (TECH) came out with quarterly earnings of $0.52 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.53 per share a year ago.
Techne (TECH) Q4 Earnings Meet Estimates
Positive
Reuters
1 month ago
Bio-Techne beats revenue estimates on research, diagnostics demand uptick
Bio-Techne beat Wall Street estimates for fourth-quarter revenue on ​Wednesday helped by growth in ‌its research and diagnostics businesses.
Bio-Techne beats revenue estimates on research, diagnostics demand uptick
Neutral
PRNewsWire
1 month ago
Bio-Techne Releases Fourth Quarter Fiscal 2026 Results
MINNEAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2026. Fourth Quarter FY2026 Highlights Fourth quarter organic revenue increased by 3% (1% reported) to $321.2 million.
Bio-Techne Releases Fourth Quarter Fiscal 2026 Results
Neutral
PRNewsWire
1 month ago
Bio-Techne Declares Dividend
MINNEAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2026. The quarterly dividend will be payable August 28, 2026, to all common shareholders of record on August 17, 2026.
Bio-Techne Declares Dividend
Price charts implemented using Lightweight Charts™